Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in Surgical Unruptured Arteriovenous Malformations
NCT06098872Phase 2Withdrawn
- Sponsor
- University Health Network
- Start
- Jan 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trametinib in arteriovenous malformation (AVM), sponsored by University Health Network. Planned start Jan 2024; status: withdrawn.
02
Drugs
trametinib
03
Conditions
arteriovenous malformation (AVM)
Beyond the preview
Go deeper on NCT06098872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098872.